Cyclerion Therapeutics Inc
NASDAQ:CYCN
Income Statement
Earnings Waterfall
Cyclerion Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-9.6m
USD
|
Operating Income
|
-9.6m
USD
|
Other Expenses
|
4.4m
USD
|
Net Income
|
-5.3m
USD
|
Income Statement
Cyclerion Therapeutics Inc
Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||
Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
2
N/A
|
3
+86%
|
5
+49%
|
6
+22%
|
5
-16%
|
4
-22%
|
2
-37%
|
1
-42%
|
4
+168%
|
4
-1%
|
4
+11%
|
5
+16%
|
1
-74%
|
1
-30%
|
2
+96%
|
0
-88%
|
1
+205%
|
1
N/A
|
0
N/A
|
|
Operating Income | ||||||||||||||||||||||||
Operating Expenses |
(108)
|
(112)
|
(115)
|
(127)
|
(132)
|
(132)
|
(130)
|
(116)
|
(102)
|
(94)
|
(85)
|
(75)
|
(73)
|
(63)
|
(58)
|
(56)
|
(33)
|
(29)
|
(46)
|
(16)
|
(18)
|
(16)
|
(10)
|
|
Selling, General & Administrative |
(19)
|
(22)
|
(28)
|
(35)
|
(36)
|
(35)
|
(34)
|
(30)
|
(28)
|
(29)
|
(29)
|
(27)
|
(27)
|
(23)
|
(21)
|
(19)
|
(15)
|
(14)
|
(15)
|
(12)
|
(11)
|
(10)
|
(8)
|
|
Research & Development |
(89)
|
(90)
|
(88)
|
(93)
|
(96)
|
(97)
|
(95)
|
(86)
|
(74)
|
(65)
|
(56)
|
(48)
|
(46)
|
(39)
|
(38)
|
(39)
|
(21)
|
(15)
|
(31)
|
(3)
|
(7)
|
(6)
|
(2)
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Operating Income |
(108)
N/A
|
(112)
-4%
|
(115)
-3%
|
(127)
-10%
|
(131)
-3%
|
(129)
+1%
|
(125)
+3%
|
(110)
+12%
|
(97)
+12%
|
(90)
+7%
|
(83)
+8%
|
(74)
+11%
|
(69)
+6%
|
(59)
+15%
|
(54)
+8%
|
(51)
+6%
|
(32)
+38%
|
(28)
+10%
|
(44)
-56%
|
(15)
+65%
|
(17)
-10%
|
(15)
+11%
|
(10)
+37%
|
|
Pre-Tax Income | ||||||||||||||||||||||||
Interest Income Expense |
0
|
0
|
0
|
0
|
1
|
2
|
2
|
2
|
2
|
1
|
1
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
2
|
2
|
(0)
|
(1)
|
(1)
|
3
|
0
|
0
|
4
|
0
|
0
|
0
|
(3)
|
(3)
|
|
Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
3
|
3
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Pre-Tax Income |
(108)
N/A
|
(112)
-4%
|
(115)
-3%
|
(127)
-10%
|
(130)
-2%
|
(128)
+2%
|
(123)
+4%
|
(106)
+14%
|
(93)
+12%
|
(85)
+9%
|
(78)
+8%
|
(71)
+9%
|
(68)
+5%
|
(60)
+11%
|
(52)
+14%
|
(51)
+1%
|
(32)
+38%
|
(25)
+22%
|
(44)
-78%
|
(15)
+66%
|
(17)
-10%
|
(18)
-9%
|
(13)
+31%
|
|
Net Income | ||||||||||||||||||||||||
Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(108)
|
(112)
|
(115)
|
(127)
|
(130)
|
(128)
|
(123)
|
(106)
|
(93)
|
(85)
|
(78)
|
(71)
|
(68)
|
(60)
|
(52)
|
(51)
|
(32)
|
(25)
|
(44)
|
(15)
|
(17)
|
(18)
|
(13)
|
|
Net Income (Common) |
(108)
N/A
|
(112)
-4%
|
(115)
-3%
|
(127)
-10%
|
(130)
-2%
|
(128)
+2%
|
(123)
+4%
|
(106)
+14%
|
(93)
+12%
|
(85)
+9%
|
(78)
+8%
|
(71)
+9%
|
(68)
+5%
|
(60)
+11%
|
(52)
+14%
|
(51)
+1%
|
(48)
+5%
|
(48)
+2%
|
(44)
+7%
|
(38)
+14%
|
(29)
+24%
|
(11)
+63%
|
(5)
+51%
|
|
EPS (Diluted) |
-77.63
N/A
|
-81.76
-5%
|
-84.12
-3%
|
-92.95
-10%
|
-94.76
-2%
|
-93.32
+2%
|
-89.78
+4%
|
-76.71
+15%
|
-67
+13%
|
-52.89
+21%
|
-51.18
+3%
|
-41.74
+18%
|
-37.77
+10%
|
-27.82
+26%
|
-26.35
+5%
|
-23.6
+10%
|
-22.01
+7%
|
-21.95
+0%
|
-20.31
+7%
|
-17.45
+14%
|
-11.18
+36%
|
-4.41
+61%
|
-2.25
+49%
|